Anzeige
Mehr »
Login
Sonntag, 19.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
100-Milliarden-Dollar-Marke: Wie die strategische Vision eines Unternehmens historischem Meilenstein passt!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
366 Leser
Artikel bewerten:
(2)

May River Capital, LLC: Cellwatch Parent, NDSL, Merges with RLE Technologies; Forms New Platform, Parameter, Strengthening Solutions for Data Centers and Critical Infrastructure Amid Surging AI Power Needs

Finanznachrichten News

CHICAGO, Dec. 12, 2024 /PRNewswire/ -- May River Capital, a Chicago-based lower middle-market private equity firm, and its portfolio company, RLE Technologies, today announced the acquisition of NDSL Group Ltd., manufacturer of Cellwatch and leading battery monitoring and management solutions for data centers, utilities, and telecom markets. The two companies will merge as a new platform company, Parameter.

May River Capital (PRNewsfoto/May River Capital, LLC)

Parameter represents the combined strengths of RLE Technologies and NDSL, with more than 70 years of collective experience providing process industry and facilities management professionals with real-time insights into mission critical operations. Parameter's advanced solutions sense, detect, monitor, analyze, and predict the quality, condition, and volume of liquids, gases, energy, and materials in their environments. Parameter serves end markets including data centers, utilities, critical infrastructure, and more.

Based in Raleigh-Durham, North Carolina, NDSL brings a 30-year history as a trusted supplier of the industry-leading Cellwatch line of products and services. NDSL's comprehensive monitoring solutions enable customers to most effectively manage their critical battery investments. Cellwatch products prevent outages, reduce costs, meet regulatory requirements, and offer the strongest durability and reliability in the industry.

Based in Fort Collins, Colorado, RLE Technologies brings a 40-year history as provider of facility environment monitoring, fluid leak detection, and airflow management products, helping facility operations professionals protect against failures that could lead to disruptions in mission critical environments.

Through a holistic approach to monitoring and management, Parameter's comprehensive portfolio of products protects the world's most valuable assets and makes the future of vital operations more predictable and manageable.

Dan Barlow, May River Capital Partner, noted: "We are excited to unite the deep teams and resources of NDSL and RLE under the Parameter banner. This merger strengthens our ability to best serve the critical infrastructure monitoring and detection needs of our customers."

"We are thrilled to be joining with RLE Technologies and rebranding as Parameter," said Earl Philmon, CEO of NDSL. "NDSL has been a trailblazer in battery asset management and monitoring, helping to prevent unplanned outages with innovative solutions. Our Cellwatch line complements RLE's products. The benefits of this union are significant, and I look forward to the growth opportunities ahead," Philmon added.

"With the support of May River, the strongest teams and the global leading technology companies in system monitoring for essential industries are brought together in Parameter. I am excited to partner with Earl and our team of experienced professionals to launch Parameter and to accelerate the advancement of future technologies and capabilities," said Mike Blazes, CEO of RLE Technologies and Parameter.

Mesirow Financial and Laytons LLP served as financial advisor and legal counsel to NDSL, respectively. Livingstone Partners LLC and Paul Hastings LLP served as financial advisor and legal counsel to May River Capital, respectively. Tree Line Capital Partners provided debt financing in support of the acquisition.

About May River Capital

May River Capital is a Chicago-based private equity firm focused on investing in lower middle-market, industrial growth companies. May River Capital invests in high-quality industrial growth businesses, including precision manufacturing, engineered products and instrumentation, specialized industrial services, and value-added industrial distribution services. For more information, please visit www.mayrivercapital.com.

About Parameter

Parameter is a new May River Capital platform company formed by the merger of RLE Technologies and NDSL. Parameter empowers process and facility management industries with real-time insights into mission critical operations. Parameter's advanced solutions sense, detect, monitor, analyze, and predict the quality, condition, and volume of liquids, gases, energy, and materials in their environments. By transforming complex data inputs into actionable intelligence, Parameter makes the future of vital operations more predictable and manageable. Parameter has operations in Fort Collins, Colorado; Raleigh-Durham, North Carolina; Milton Keynes, United Kingdom; and Shanghai, China. To learn more, please visit www.parameter-tech.com.

Logo - https://mma.prnewswire.com/media/2256500/May_River_Capital_LLC_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/cellwatch-parent-ndsl-merges-with-rle-technologies-forms-new-platform-parameter-strengthening-solutions-for-data-centers-and-critical-infrastructure-amid-surging-ai-power-needs-302328283.html

© 2024 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.